Sou Hu Cai Jing·2025-11-12 19:36Core Viewpoint - Southbound funds have increased their holdings in Fosun Pharma (02196.HK), indicating growing investor confidence in the company [1]. Group 1: Shareholding Changes - On November 12, 2025, southbound funds increased their holdings by 97,500 shares, representing a change of 0.03% [2]. - Over the past five trading days, there have been four days of net increases, totaling 2.72 million shares [1][2]. - In the last 20 trading days, there were 13 days of net increases, amounting to 6.41 million shares [1]. Group 2: Current Shareholding Status - As of now, southbound funds hold a total of 314 million shares of Fosun Pharma, which accounts for 56.85% of the company's issued ordinary shares [1][2]. Group 3: Company Overview - Fosun Pharma is primarily engaged in the research, manufacturing, and sales of pharmaceutical products, operating through five segments [2]. - The pharmaceutical segment focuses on innovative drugs, mature pharmaceutical products, and vaccines [2]. - The medical devices and diagnostics segment is involved in the manufacturing and sales of molecular diagnostics, immunodiagnostics, and microbiological diagnostic devices [2]. - The healthcare services segment operates an integrated online and offline medical service platform [2]. - The pharmaceutical distribution and retail segment is responsible for the wholesale and retail of pharmaceutical products [2]. - The company's products are mainly used in the treatment of oncology, immunology, and central nervous system disorders [2].